AI
| Followers | 2528 |
| Posts | 250766 |
| Boards Moderated | 33 |
| Alias Born | 05/06/2014 |
Tuesday, February 06, 2018 5:49:00 PM
$DFFN Breaking News DFFN
“We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “We believe that this Phase 3 study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies.”
http://investors.diffusionpharma.com/file/Index?KeyFile=391934667
“We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “We believe that this Phase 3 study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies.”
http://investors.diffusionpharma.com/file/Index?KeyFile=391934667
investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
